[Treatment of anti-thrombotic therapy in coronary artery disease]

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• Anti-platelet therapy, including dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, is standard for coronary artery disease (CAD) and post-stenting.
• Drug-eluting stents (DES) reduce restenosis but are linked to increased long-term stent thrombosis, potentially due to CYP2C19 polymorphisms affecting clopidogrel efficacy.
• Long-term DAPT is necessary to prevent stent thrombosis but can cause bleeding complications.

Purpose of the Study:

• To review the evolution of anti-thrombotic treatments for CAD patients.
• To discuss current and emerging therapeutic strategies.
• To explore the potential role of novel oral anticoagulants (NOACs) in CAD management.

Main Methods:

• Review of existing literature on anti-thrombotic therapies in CAD.
• Discussion of clinical trial data regarding new anti-platelet agents and NOACs.
• Analysis of the benefits and risks associated with different anti-thrombotic regimens.

Main Results:

• DAPT effectively reduces major adverse cardiovascular events in CAD patients.
• Stent thrombosis remains a concern with DES, prompting research into alternative anti-platelet strategies.
• NOACs are established for stroke prevention in atrial fibrillation and are under investigation for CAD.

Conclusions:

• Anti-thrombotic treatment for CAD has advanced significantly, with ongoing research into safer and more effective options.
• Balancing the prevention of thrombotic events against bleeding risk is crucial in managing CAD.
• Novel anticoagulants and anti-platelet agents represent the future direction for anti-thrombotic therapy in CAD.